Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Preoperative MRI.
- Who it may be relevant to
- Registry conditions: Pancreatic Cancer, Pancreatic Neoplasm, Liver Metastases. Basic parameters: 18 years — 99 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Denmark
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery (MAGIPAC): A Randomized Clinical Trial.
Overview
The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients.
Detailed description
The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients. We will conduct a nationwide, prospective clinical trial to examine the incremental value of using MRI for identification of liver metastases in pancreatic cancer patients.
Interventions
- Diagnostic test Preoperative MRI
Preoperative MRI performed between outpatient visit at the surgical clinic and scheduled date of resection
Primary outcome measures
- Change in treatment strategy [Time frame: 1 week]
Secondary outcome measures (8)
- Liver metastases [Time frame: 1 week]
- Surgery [Time frame: 1 month]
- Resection [Time frame: 1 month]
- Intraoperatively detected liver metastases [Time frame: 1 month]
- Overall survival (1-year) [Time frame: 1 year]
- Overall survival (3-year) [Time frame: 3 years]
- Recurrence-free survival [Time frame: 3 years]
- Healthcare costs [Time frame: 3 years]
Eligibility criteria
Inclusion criteria
- Pancreatic cancer patients considered to have a locally resectable or borderline resectable tumor by the local hepato-pancreato-biliary multidisciplinary team board
- No liver metastases on CT
- At least 18 years old and able to provide informed consent
- Expected pancreatic ductal adenocarcinoma based on CT scan
Exclusion criteria
- Metastatic disease
- Prior receipt of neoadjuvant chemotherapy or downstaging/-sizing treatment
- Comorbidity rendering major surgery unfeasible (inoperable)
- No informed consent
- Unable to undergo MRI (Kidney insufficiency (eGFR < 60 ml/min/1.73 m2 body surface ar-ea); Claustrophobia; Cardiac pacemaker)
- Postoperative histology other than adenocarcinoma of pancreato-biliary origin.
- MRI with liver-specific contrast performed during standard workup.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
Denmark · 3 centers
- Aalborg University Hospital — Aalborg
- Aarhus University Hospital — Aarhus
- Rigshospitalet — Copenhagen
Identifiers
NCT: NCT05428358 · MAGIPAC